(Press-News.org) SEATTLE – A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease. The results of the study, led by Hutchinson Center computational biologist Harlan Robins, Ph.D., are reported in the May 16 issue of Science Translational Medicine.
"The ability to predict disease relapse sooner with high-throughput sequencing would give hematologists the option to treat cancer recurrence earlier, offering a greater chance of survival. Longer term, this technology potentially also could be used to initially diagnose leukemia and lymphoma much earlier than we can today," said Robins, an associate member of the Hutchinson Center's Public Health Sciences Division and corresponding author of the paper.
For the study, Robins and colleagues compared the effectiveness of high-throughput sequencing versus flow cytometry to detect minimal residual disease in 43 patients diagnosed with acute T lymphoblastic leukemia, a type of blood cancer that is most common in children under age 7. By sequencing the patients' T-cell receptor genes before and 29 days after chemotherapy, the researchers were able to precisely measure their presence in the blood and provide a more accurate prediction of leukemia relapse.
"The high-throughput sequencing detected minimal residual disease in nearly double the number of patients than flow cytometry – 22 versus 12 patients, respectively," Robins said.
Minimal residual disease, or MRD, a major predictor of cancer relapse, is when a small number of cancer cells survive treatment and persist in patients. Until recently, MRD was undetectable.
Flow cytometry, the primary method for detecting MRD in the United States, counts the number of cells in the blood with cancer-specific protein markers on their surface. While it is considered the gold standard, flow cytometry comes with a number of limitations:
it has been difficult to standardize across different labs because there is no standard protocol;
the antibodies used to tag the cancerous cells are expensive;
every cancer type requires a different test, because each malignancy is associated with a different protein marker; and
the sensitivity of the test is low, which means it sometimes fails to recognize the presence of cancer cells.
This study – the first use of high-throughput sequencing, or HTS, to detect minimal-residual disease in a clinical trial setting – found it to be at least 20 times more sensitive than flow cytometry in detecting MRD.
"Our research indicates that HTS offers many advantages over flow cytometry," Robins said. "Since HTS can detect any pre-identified clone and is performed in a centralized lab, it consistently generates reproducible and reliable results regardless of cancer type, using the same process for disease detection and tracking. Furthermore, HTS is highly automated, cost-effective and objective, whereas flow cytometry is more time consuming, relies on the skill of the operator and is therefore subject to human error."
The Hutchinson Center has patents pending on core technologies employed by Robins and colleagues in conjunction with high-throughput DNA-sequencing used for this study. These core technologies have been licensed exclusively to Adaptive Biotechnologies, a Seattle biotechnology company Robins co-founded that offers commercial DNA sequencing and analysis.
Robins and colleagues discovered how to adapt traditional high-throughput technology to sequence only variable regions of the human genetic code: the T- and B-cell receptors – a critical component of the human adaptive immune system. These receptors are short strands of DNA that constantly rearrange to allow the immune system to fight viruses, infection or disease.
"This discovery was critical to our understanding of how patients mount immunological responses against cancer, autoimmune disorders and infectious diseases," said Robins, whose Hutchinson Center research focuses on the genetics of the immune system – particularly how it responds to pathogens and the aging process.
INFORMATION:
Co-authors on the paper included researchers from the University of Washington, Adaptive Biotechnologies, the University of New Mexico, the University of Virginia and the University of California at San Francisco. Funding for the work was provided by the University of Washington Department of Laboratory Medicine; Becton, Dickinson and Co. of New Jersey; and Children's Oncology Group.
At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit www.fhcrc.org.
END
While the mobile community continues to grow, Dr. Hahn, dentist in Kentwood, MI, is happy to offer an advanced mobile website to better meet the needs of patients who are constantly on the go. Today, in a technologically advanced society, more and more people are utilizing their smart phones and tablet devices for their daily needs. From ordering food to looking up important information, patients use their smart phones and tablet devices on a daily basis.
By offering a mobile website, Dr. Hahn, dentist in Kentwood, enhances his patients' ability to receive important ...
Common variants of the ApoE gene are strongly associated with the risk of developing late-onset Alzheimer's disease, but the gene's role in the disease has been unclear. Now, researchers funded by the National Institutes of Health have found that in mice, having the most risky variant of ApoE damages the blood vessels that feed the brain.
The researchers found that the high-risk variant, ApoE4, triggers an inflammatory reaction that weakens the blood-brain barrier, a network of cells and other components that lines brain's brain vessels. Normally, this barrier allows ...
Dr. Greg Herzler, Saginaw Township dentist, appreciates his patients' feedback about his practice. By leaving reviews, patients help Dr. Herzler to improve his practice to better serve his patients. Patients can visit the practice's website for instant access to available links to leave their feedback on the review site of their choice.
"I always look forward to hearing from my patients about their experience with my office. By leaving reviews, my patients allow me to constantly improve my practice and the way we serve our patients. I hope to continue to provide ...
The movement patterns of critically endangered leatherback turtles vary greatly depending on whether the animals live in the North Atlantic or the Eastern Pacific, with implications for feeding behavior and population recovery, according to research published May 16 in the open access journal PLoS ONE.
The authors, led by Helen Bailey of the University of Maryland Center for Environmental Science, found that turtles in the Atlantic had two travel modes, low and high speed, associated with foraging and transit, respectively. The Pacific turtles, on the other hand, only ...
Multidrug-resistant pathogens are becoming more frequent, and the few "last resort" treatments available for infections with these bacteria have also shown an increase in use in recent years, according to a study published May 16 in the open access journal PLoS ONE.
The authors, led by Makoto Jones of the Veterans Affairs Salt Lake City Health Care System, investigated the use of two such antibiotics, polymyxins and tigecycline, in 127 Veterans Affairs medical centers between 2005 and 2010. They found that the overall use of these treatments was quite low, but that it ...
Leading dentist in Flushing and Flint, MI, Dr. Scott Pelok, is pleased to introduce the practice's newest piece of dental technology- the Galileos 3D cone beam scanner. The new dental diagnostic system is helping the practice continue to bring patients the most efficient, comfortable and effective dentistry possible.
The new Galileos 3D diagnostic system allows Dr. Pelok and his team to create a precise 3D image of a patient's entire jaw in a matter of seconds- in significantly less time than traditional x-rays. The Galileos advanced technology allows patients to be ...
In 1848, railroad worker Phineas Gage survived a severe brain injury when a tamping rod shot through his skull, resulting in significant behavioral changes. In a new study, reported May 16 in the open access journal PLoS ONE, researchers have used CT images of his skull in conjunction with MRI and connectomic brain imaging data of living subjects to reconstruct the injury and investigate which regions of the brain were affected to result in the behavioral changes.
The research team, led by John Van Horn of University of California Los Angeles, found that considerable ...
DURHAM, N.C. – What can a fish tell us about human brain development? Researchers at Duke University Medical Center transplanted a set of human genes into a zebrafish and then used it to identify genes responsible for head size at birth.
Researchers at Duke University Medical Center transplanted a set of human genes into a zebrafish and then used it to identify genes responsible for head size at birth.
Head size in human babies is a feature that is related to autism, a condition that recent figures have shown to be more common than previously reported, 1 in 88 children ...
Boston, MA ─ A new study from Harvard School of Public Health (HSPH) and the World Health Organization (WHO) found that a simple checklist-based childbirth safety program dramatically improved adherence to essential childbirth care practices at a pilot hospital in south India. Of 29 practices measured, 28 were improved after adoption of the checklist and overall adherence to essential practices was 150% better after the checklist was introduced.
"This is a significant step forward because it provides hope that use of this simple, low-cost tool can help birth attendants ...
PHILADELPHIA – A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine. Senior authors of the study are Robert H. Vonderheide, MD, DPhil, associate professor of Medicine, and James Riley, PhD, associate professor of Microbiology.
The team ...
